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Ronan Astin1* and Zudin Puthucheary1,2,3Abstract
Almost all patients suffering critical illness become anaemic during their time in intensive care. The cause of this
anaemia and its management has been a topic of debate in critical care medicine for the last two decades. Packed
red cell transfusion has an associated cost and morbidity such that decreasing the number of units transfused
would be of great benefit. Our understanding of the aetiology and importance of this anaemia is improving with
recent and ongoing work to establish the cause, effect and best treatment options. This review aims to describe
the current literature whilst suggesting that the nature of the anaemia should be considered with reference to the
time point in critical illness. Finally, we suggest that using haemoglobin concentration as a measure of oxygen-carrying
capacity has limitations and that ways of measuring haemoglobin mass should be explored.
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Introduction
Critically ill patients are regularly classified by physiological
syndromes such as acute respiratory distress syndrome
(ARDS), multi-organ dysfunction syndrome (MODS), sys-
temic inflammatory response syndrome (SIRS), or clinical
diagnoses such as severe sepsis, acute kidney injury or
traumatic brain injury. These nomenclatures hide both the
heterogeneity of the patients’ presentation and the diverse
diseases from which they may suffer pre-critical illness.
Strikingly, despite this variation, it has been repeatedly
shown that the vast majority of all patients requiring inten-
sive care support display a falling haemoglobin concentra-
tion ([Hb]), with the majority becoming anaemic (as
defined [Hb] <130 g/L in males and <120 g/L in females)
[1-4]. The cause of this falling [Hb] is not clear nor its im-
pact on patient outcomes. This review considers the time
frame of anaemia of critical illness and suggests that the
aetiology is related to the illness phase. The likely causes of
anaemia will be discussed, and the evidence for impact on
patient outcome considered. Finally, the limitations of using
[Hb] as an indicator of oxygen-carrying capacity will be* Correspondence: ronan.astin@nhs.net
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2014outlined, and the advantages of using total Hb-mass
(tHb-mass) will be discussed.Time course of anaemia in critical illness
Defining the temporal relationship between anaemia and
critical illness is best done by dividing critical illness into
three time periods:
 Pre-ICU admission
 The acute phase, covering approximately the first 7
days of ICU admission
 The chronic stage thereafter
Little is known regarding [Hb] in the lead up to ICU
admission, but it is clear that on entering critical care, a
large proportion of patients already have a low [Hb].
Two large studies demonstrated this; in 3,534 general
admissions to ICUs in Western Europe enrolled in the
ABC trial, the mean admission [Hb] was 113 ± 23 g/L
and 29% had [Hb] <100 g/L [5], whilst in the 4,892 subjects
enrolled to the CRIT study in general ICUs in North
America, the mean baseline [Hb] was 110 ± 24 g/L [3]. A
more recent study has put the proportion of patients ad-
mitted to ICU with [Hb] in the anaemic range even higher
at 86% [6]. In a study of 1,023 patients admitted to 10 gen-
eral ICUs in Scotland (ATICS study) each with a medical,
surgical and trauma case-mix, the mean admission [Hb]d Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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data from multiple large studies, Walsh and Saleh have
estimated that 60% to 70% of patients are anaemic on en-
tering ICU with 20% to 30% displaying [Hb] <90 g/L [8].
However, the chronic (or non-chronic) nature of pre-ICU
anaemia has not been widely studied. For the majority,
though it seems unlikely to be longstanding; in both the
ABC and CRIT studies, the proportion of patients entering
ICU with a medical history of anaemia was only 13%.
The acute anaemia of critical illness
Over the first few days of admission to critical care, [Hb]
continues to fall. In a study of 155 ICU patients in a
general ICU, the mean admission [Hb] was 111 ± 25 g/L
but by the second time point on day 7, this had fallen to
94 ± 14 g/L [2]. This is a pattern repeatedly demon-
strated [6,9,10]. In the CRIT study, 44% of subjects re-
quired one or more units of packed red cells (PRC)
transfused during their stay in ICU and the majority of
these transfusions occurred early in their admission with
a mean time to first transfusion of 2.3 ± 3.7 days (mean
pre-transfusion [Hb] 86 ± 17 g/L from an admission level
of 111 g/L) [3]. Chohan et al. showed that in a cohort
of 176 patients admitted to a general ICU, 52% had
[Hb] <90 g/L on day one increasing to 77% by day two
[11]. Nguyen et al. further defined the time course of this
drop by demonstrating that over the course of an ICU stay,
[Hb] fell on average 5.2 ± 6.9 g/L per day, but the decline
was greatest over the first 3 days when [Hb] declined by
6.6 g/L per day compared to 1.2 ± 2.9 g/L per day there-
after [4]. Importantly, these patients had no history of
acute or recent blood loss, haematological disease, chronic
renal dysfunction or renal replacement therapy. In this
study, there was an inverse correlation between [Hb] de-
cline and markers of illness severity (APACHEII) (r2 = 0.28,
p < 0.001). This rapid drop in [Hb] seems then to be related
to severe illness, commencing before ICU admission and
continuing for a short time after.
Chronic anaemia in critical illness
In Nguyen’s study, there was a distinct drop-off in rate
of [Hb] decline after the first 3 days. For those patients
remaining in ICU >3 days, [Hb] decreased by 6.6 ± 8.4 g/L
per day for the first 3 days and by 1.2 ± 2.9 g/L per day
thereafter whilst for patients remaining in ICU >1 week,
[Hb] dropped by 5.8 ± 6.4 g/L per day for the first 3 days
and by 2.1 ± 2.3 g/L per day thereafter. This emphasizes
two points: the decline in [Hb] after the acute drop slows
markedly, but there is a subsequent progressive decrement
in [Hb]. Describing this chronic phase in clinical studies is
made difficult by blood transfusion interventions and vary-
ing transfusion practices [8]. Considering ongoing transfu-
sion requirements alongside the associated transfusion
trigger is one method of description. In a study by Corwinet al. of patients staying in ICU >7 days, 85% received one
or more units of blood at some point in their stay; 40%
were transfused only in the first week, but the remaining
60% of patients transfused after week one had an ongoing
transfusion requirement of 2 to 3 units/week thereafter
with a mean pre-transfusion haematocrit of 27% [12].
Whilst outdated phlebotomy practices accounted for
some of this requirement (discussed below), more recent
studies have shown a similar chronic transfusion need. In
a prospective study of 100 consecutive admissions to a
general ICU, the transfusion rate was 40% overall, though
this climbed to 70% in those remaining in ICU >7 days
[6]. In this study, the average pre-transfusion [Hb] was
73.5 ± 4.7 g/L and there was no association between
transfusion and phlebotomy practices. Chant et al. reported
the [Hb] variations in patients remaining in ICU for more
than 30 days, excluding those with active bleeding; they
found that 49% of patients received one or more PRC units
after day 21 (with a mean transfusion trigger of 77 g/L),
and those who received a transfusion had higher mean
daily sequential organ failure assessment (SOFA) scores
and requirements for organ support therapies [2]. Finally,
considering [Hb] at discharge, Walsh et al. showed that
87% were anaemic, with 24% of men and 28% of women
discharged with [Hb] <90 g/L [7] whilst in a small study of
19 critical care survivors, 53% were still anaemic 6 months
after their discharge [13].
Aetiology of anaemia
An exhaustive discussion of the possible aetiologies is be-
yond the scope of this review. However, given the quite
clear distinction between the acute and chronic [Hb] drop
in the course of critical illness, it stands to reason that dif-
ferent mechanisms may be responsible for the [Hb] decline
over these time periods; it is this that will be focused on.
Haemorrhage
In the ATICS study, of the 1,028 subjects enrolled, only
4% had a history of bleeding at ICU admission [7].
Cook et al. showed that in 1,014 mechanically ventilated
patients, the incidence of clinically important gastrointes-
tinal bleeding was 2.8% [14]. Furthermore, in Nguyen’s
study, any patients with a history of recent bleeding or
surgery (except where blood loss was negligible) were
excluded. This suggests that the acute drop in [Hb] cannot
be explained by haemorrhage. In contrast, a proportion of
the chronic anaemia can be explained by blood loss
events; in the ATICS study, clinically significant haemor-
rhage occurred in 21% of ICU patients and accounted for
40% of all transfusion episodes [15]. However, of all the
patients transfused in this observational study, 54.7% re-
ceived transfusions that were not associated with clinically
significant haemorrhage emphasizing the importance of
other causes of chronic anaemia in the critically ill.
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Figure 1 The effect of haemodilution on full blood count
parameters. Fluid resuscitation increases the plasma volume (PV)
without increasing red cell volume (RCV), resulting in a drop in
Hb concentration.
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Studies in the mid 1980s demonstrated the link between
phlebotomy in critical care and transfusion requirement
[16]. Then, being admitted to ICU increased blood sam-
pling from a mean of 1.1 times a day to 3.4 times a day
(or four times a day if there was an indwelling arterial
catheter) incurring a mean blood volume loss of 41.5 ml
per day [17] potentially accounting for the development
of anaemia. Since the introduction of conservative phle-
botomy techniques, it has been shown that though the
average number of phlebotomies has not changed (mean
of 3.5 ± 1.04 (SD) per patient per day), the mean blood
loss can be reduced to between 8 and 22 ml per day
[2,6,18], and with this, the acute drop in [Hb] over the
first 3 days is independent of phlebotomy [6].
In those that remain in ICU >7 days, evidence suggests
that ongoing phlebotomy may contribute significantly to
anaemia. Chant et al. showed that after day 21, the num-
ber of units of RBCs transfused was significantly and in-
dependently associated with daily phlebotomy volume
even when adjusted for other confounders [2].
Fluid status and haemodilution
Haemodilution occurs when plasma volume is expanded
with no change in Hb-mass, resulting in an increased
volume of distribution and consequently a decreased [Hb].
On admission to ICU, the volaemic status of the patient is
assessed and addressed to maintain appropriate circulatory
volume and pressure. It is often necessary to give intravas-
cular fluid in a continuous infusion or bolus form, conse-
quently haemodiluting the patient (Figure 1). The current
literature does not allow us to attribute acute anaemia to
haemodilution; most studies have not accurately measured
or accounted for plasma volume in their analysis. Of those
that included a measure of fluid status, Nguyen et al. found
that fluid balance during the first 3 days did not signifi-
cantly influence the fall in [Hb] [4] (though fluid status was
recorded only as 24-h fluid balance). Fully accounting for
haemodilution in the acute anaemia in ICU will remain a
challenge whilst [Hb] is used as the marker of oxygen-
carrying capacity. The advantages of using tHb-mass in-
stead will be discussed later in the article.
Erythropoietin deficiency
Erythropoietin (EPO) is the major hormone regulating
new red cell production in the bone marrow by inhibit-
ing apoptosis of erythrocytic progenitor cells whilst also
slowing the turnover of mature red blood cells in the
reticuloendothelial system. A deficiency in EPO there-
fore leads to a fall in Hb. Whilst the absolute EPO levels
in critical illness are not decreased [19], there is evidence
for a blunted EPO response in critically ill septic patients
[9,20-23]. The likely mechanism is the inhibition of the
EPO gene response elements by cytokines (IL-1, IL-6,TNFα) [24,25] which are known to be increased in sepsis
[26,27]. This contributes to the chronic anaemia of critical
illness (in much the same way as in the anaemia of chronic
disease) [28], but it cannot account for the acute drop in
[Hb] as the effect of a fall in EPO (absolute or relative) on
progenitor cell maturation would only be reflected in a fall-
ing [Hb] after approximately 10 days [29].
Haemopoietic nutrient deficiency
Efficient erythropoiesis requires not only sufficient EPO
but also the availability of haemopoietic nutrients. There
is evidence that in a proportion of critical ill patients,
there is a deficiency in B12, folate and iron either in ab-
solute or functional terms. In a study by Rodriguez et al.
in non-bleeding, non-haemolysing medical ICU patients,
on day 2 or 3 of ICU admission, 13% were found to have
nutritional deficiencies that could contribute to anaemia
(9% iron deficiency, 2% B12 deficiency, 2% folate defi-
ciency) [30]. The burden of nutrient deficiency may even
be higher than this due to the difficulty in assessing iron
status during critical illness [31,32]; as an acute phase
protein, ferritin is usually raised in critically ill patients
without a change in total body ferritin [33] meaning that
a ‘normal’ ferritin may actually reflect a total body def-
icit. In this way, the anaemia of critical illness resembles
that of chronic disease. There is also evidence that intes-
tinal absorption of iron may be limited in critical illness
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tein hormone which plays an important role in iron
homeostasis by influencing intestinal iron absorption and
iron release into the plasma from macrophages [34]. This
occurs through interaction with the ferroportin trans-
porter [35] which is expressed by enterocytes and reticulo-
endothelial macrophages. Increased hepcidin levels lead
to decreased intestinal iron absorption and sequestration
of iron within macrophages. Inflammation and infection
increase hepcidin synthesis probably through IL-6 stimu-
lation, and there is evidence that in critical illness, hepci-
din levels are elevated [36]. This may be part of an
evolutionary mechanism to protect against bacterial infec-
tion since bacteria require iron to support their growth
[31]. Subsequent iron deficiency may be an unintended
consequence. Furthermore, the inability to incorporate
iron into erythroid precursors despite the presence of
adequate iron stores, termed functional iron deficiency
(FID), may result in ineffective haematopoiesis in the pres-
ence of ‘normal’ serum iron values. Patteril et al. showed
that FID, as measured by red cell hypochromasia on flow
cytometry, was present in 35% of 51 consecutive admis-
sions in a medical ICU [37].
However, haemopoietic nutrient deficiency alone can-
not explain the anaemia of critical illness; the prevalence
of deficiency is low, in Patteril et al.’s study, there was
no difference in [Hb] between FID and non-FID groups
[37], and whilst nutrient insufficiency may contribute to
chronic anaemia in critical illness, as with EPO insuffi-
ciency, the mechanism of decreased red cell production
cannot explain the fall in [Hb] over the first few days.
Neocytolysis
Neocytolysis describes the programmed destruction of
new red cells (neocytes). It is a mechanism first de-
scribed in astronauts returning to earth after space flight
[38,39] and subsequently in climbers returning from
high altitude [40,41]. In both situations, it is used to ex-
plain how red cell mass can be modulated over a short
time frame of a few days leading to rapid reduction in
[Hb]; in a study of astronauts returning from space
flight, red cell mass was reduced by 10% to 15% over 7
to 10 days [42]. Although the mechanism has not been
clearly defined, it appears that neocytolysis is dependent
on red cell splenic endothelial cell-macrophage inter-
action. The likely mechanisms are summarized in Figure 2.
The first is dependent on decreased serum EPO levels
whilst the second involves oxidative damage in neocytes.
Work by Song et al. in a mouse model of neocytolysis
in the setting of hypoxia-induced polycythaemia demon-
strated that reticulocytes exposed to hypoxic conditions
during maturation have an increased mitochondrial mass
but lower levels of the reactive oxygen species (ROS)
scavenging enzyme, catalase [43]. This leads to oxidativedamage in the mature reticulocyte and expression of phos-
phatidylserine on their outer membrane and subsequent
splenic consumption. Given the inflammatory state com-
mon to most critical illnesses, it is likely that erythroid
progenitors are exposed to oxidative stress to oxidative
stress during maturation and thus might follow this path-
way. No studies have yet demonstrated neocytolysis in
critical illness but it would provide a plausible explanation
for the acute fall in [Hb] which cannot easily be explained
otherwise and may contribute to the ongoing anaemia of
the chronic phase. However, to suggest that neocytolysis
occurs as a programmed response to critical illness is to
suggest that tHb-mass is purposefully downregulated.
Anaemia and outcome in critical illness
Evaluation of the effect of anaemia on outcome in crit-
ical illness is complicated by the impact of PRC transfu-
sions. In addition to the complications applicable to all
transfusion recipients (volume overload, transfusion-
related lung injury (TRALI) and anaphylaxis), in the crit-
ically ill, there is evidence that transfusion of PRCs can
cause immunomodulation, lead to increased incidence of
nosocomial infection [44] and is associated with longer
ICU stay [3] and greater mortality independent of organ
dysfunction [3,5,44,45]. The more severely anaemic pa-
tients are likely to be exposed to more transfusions and
associated risk, confounding the risk of anaemia alone.
The TRICC trial provides some evidence to suggest that
anaemia in critical illness is not necessarily harmful, with
particular reference to acute anaemia [46]. This random-
ized study of non-bleeding critically ill patients with a
[Hb] <90 g/L within the first 3 days of ICU admission
compared a liberal transfusion strategy (transfusion trigger
[Hb] <100 g/L, [Hb] aim 100 to 120 g/L) to a restrictive
strategy (transfusion trigger [Hb] <70 g/L, [Hb] aim 70 to
90 g/L). The result strongly suggests restricting blood
transfusions to the lower trigger, with no difference in
overall outcome between the groups, but a trend towards
lower mortality in the restrictive group, particularly in the
younger and less severely ill subgroup. The study did not
use leucodepleted packed red cells and the storage age of
the blood was unknown, both of which may have in-
creased the adverse events in the liberal group. However,
there is general agreement that a restrictive policy should
be followed in most patients, with the exception of ischae-
mic cardiac cases where clarity is still required [47,48]. A
smaller study conducted recently in 167 critically ill pa-
tients confirmed the lack of harm associated with a trans-
fusion trigger of 70 g/L [10]. Outside critical illness, the
same has been shown in high-risk patients undergoing hip
surgery [49] and in upper gastrointestinal bleeds where a
restrictive strategy significantly improved outcomes [50].
There is also reason to believe that [Hb] lower than 70 g/L
may be well tolerated; clinical reports of Jehovah’s Witness
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Figure 2 Proposed mechanism of neocytolysis. As the apparent concentration of EPO decreases, the permeability of the splenic endothelial
cells (EC) increase (1) possibly secondary to an increase in macrophage-derived vascular endothelial growth factor (VEGF). ECs are stimulated to
produce inflammatory cytokines along with VEGF (2) which cause upregulation of adhesion molecules on neocyte (NC) outer membranes and
expression of phosphatidylserine (3). Macrophage processes interact with the neocytes and initiate eryptosis (4). Alternatively, erythroid progenitors (EP)
in the bone marrow exposed to inflammatory conditions increase mitochondrial mass (5) which subsequently increases ROS production (6) and
phosphatidylserine expression.
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increases when [Hb] fell below 50 g/L [51]. A recent meta-
analysis of 19 randomized controlled trials investigating an-
aemia in critical illness from 1956 onwards and including
6,264 patients showed that there is no association between
a lower transfusion threshold ([Hb] 60 to 80 g/L) and any
significant complication or outcome measure [52].
There are several reasons why transfusion of PRCs in
critical illness may not be beneficial. First, anaemia may
confer beneficial effects on cardiac output and flow charac-
teristics in the peripheral circulation. In healthy humans,
the decreased viscosity that accompanies anaemia leads to
decreased left ventricular outflow impedance resulting in
an increase in cardiac output [53-55]. Second, anaemia is
associated with decreased systemic vascular resistance [56]
whilst an increased haematocrit causes an increase in vis-
cosity and increased vascular resistance [57]. Additionally,
changes to red cell rheology and function occur in critical
illness with decreased deformability [58] and increased
interaction with the endothelium likely contributing to
microcirculatory pathology [58-61]. In this setting, anaemia
may improve peripheral perfusion.
Oxygen delivery in critical illness
Other than treating haemorrhage, the most cited indica-
tions for the transfusion of PRC units in ICU are low [Hb]and to increase oxygen (O2) delivery (DO2) [5,15,62]. DO2
is determined by cardiac output (CO) and the oxygen con-
tent of the arterial blood (CaO2) can be expressed as:
DO2 ¼ CO CaO2
CaO2 is dependent on the plasma concentration of Hb,
the oxygen-binding capacity of Hb (usually considered to
be 1.34 ml O2 per gram Hb) and the plasma partial pres-
sure of O2 (which itself is a function of the solubility factor
of oxygen at body temperature (0.23 ml l−1 kPa−1). This
can be calculated as follows:
CaO2 ¼ Hb½   arterialO2 saturation 1:34 ml O2=gHbð Þ
þ 0:23 PaO2ð Þ
Using this equation, transfusion of PRCs does increase
DO2 in critically ill patients [63]. However, in the critically
ill, this does not translate to an increase in oxygen
utilization (as measured by oxygen consumption, VO2) in
the tissues [8,64,65]. In a group of septic anaemic patients,
Fernandes et al. demonstrated, by way of gastric tonometry
and calorimetry, no increase in global or regional oxygen
utilization following PRC transfusion [66], whilst Creteur
et al. showed no consistent improvement in muscle oxygen
utilization using near-infrared spectroscopy (NIRS) in all-
comer ICU patients following transfusion [67].
Table 1 The relative contribution of [Hb], inspired oxygen
and tHb-mass on oxygen-carrying capacity
Normal Anaemic Anaemic +
oxygen
Decreased
tHb-mass
Inspired oxygen (%) 21 21 100 21
PaO2 (kPa) 12 12 85 85
SaO2 (%) 98 98 98 98
Hb concentration (g/L) 150 75 75 75
Dissolved oxygen (ml/L) 3 3 19 3
Hb bound oxygen (ml/L) 197 98 98 98
tHb-mass (g) 750 500 500 400
Total CaO2[Hb] (ml/L) 200 101 117 101
Total CaO2 (tHb-mass) (ml) 988 660 676 528
Adapted from SA McLellan [85] with permission. PaO2, arterial partial pressure
of oxygen; SaO2, arterial oxygen saturation; tHb-mass, total haemoglobin mass;
CaO2 [Hb], oxygen-carrying capacity using [Hb]; CaO2 [tHb-mass], oxygen-carrying
capacity using tHb-mass.
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be explained by alterations in the oxygen-carrying and
delivery capacity of transfused blood as a consequence of
their storage, termed the ‘storage lesion’. These changes in-
clude decreased deformability [68] and alterations in ATP
and 2,3 DPG levels [69]. The effect of these changes would
be decreased RBC capillary flow and decreased oxygen off-
loading, which are not taken into account by the calcula-
tion of DO2 outlined above. However, the storage lesion is
an in vitro phenomenon, and it is not clear whether these
findings are replicated in vivo [70] though a clinical study
investigating the effect of RBC storage on clinical outcomes
is currently underway [71].Figure 3 Phases of critical care anaemia.Whether there is a storage lesion or not, there is evi-
dence that rather than oxygen delivery failure, the prob-
lem occurs in failure to utilize the oxygen delivered;
increased tissue oxygenation has been shown in the blad-
der epithelium of a rat model of sepsis [72] whilst in-
creased muscle tissue oxygen tension has been shown in
ICU patients with systemic sepsis compared with controls
[73,74]. Meanwhile, oxygen consumption (measured by
VO2max) decreases in sepsis and correlates with severity of
sepsis [75]. Mitochondria are the sites of oxygen utilization,
and as such, these data point toward mitochondrial dys-
function, of which there is increasing evidence [76-79].
This has led to the theory of cellular hibernation pro-
posed by Singer [80,81] which states that in the setting
of sepsis, within the milieu of inflammatory cytokines
and cellular dysfunction, maintaining mitochondrial mass
and respiration in non-critical organs would result in in-
creased ROS production (and potential harm to the cell)
and would place an unnecessary energy demand on the
body as a whole (in manufacturing mitochondrial proteins,
regulating mitochondrial turnover, etc.). Instead, the cell
enters a state akin to hibernation. In this situation, there is
adaptive cell hypoxia where low pO2 can be tolerated due
to adaptive changes in the drivers of electron transport
[82-84]. This seems to be supported by evidence of early
mitochondrial biogenesis being associated with survival in
septic patients [78].
Overall, the extreme physiology of critical illness in-
cluding adaptive cell hypoxia means that the usual em-
ployment of ‘normality’ in reference to Hb levels is
unhelpful. The assumption that a normal [Hb] is required
to optimize outcomes has been disproved. More work is
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lie [52].
tHb-mass and critical illness
In discussing the anaemia of critical illness, a major
limitation is the inherent inaccuracy associated with
measuring oxygen-carrying capacity by [Hb] rather than
tHb-mass. Concentration is dependent on the circulatory
volume. As discussed previously, the fluid status of pa-
tients entering ICU differs significantly. For any given
[Hb], patients may have very different tHb-masses [85].
Table 1 demonstrates the importance of considering tHb-
mass rather than [Hb] when calculating DO2. Consider-
ing a constant [Hb] of 75 g/L, increasing the inspired
oxygen from 21% to 100% increases the CaO2(tHb-mass)
by 16 ml. However, if we consider that despite a constant
[Hb], actual tHb-mass might vary by 20%; this causes
a 132-ml drop in CaO2(tHb-mass). Furthermore, since
haemodilution occurs early in ICU admission but to
varying degrees, not only the initial [Hb] but also its
trend cannot be relied upon as a marker of oxygen-
carrying capacity. Studies investigating indications for
blood transfusion in ICU have repeatedly found that in-
creasing oxygen-carrying capacity [46,86] and low [Hb]
[5,62] are the most frequently reported reasons. It is likely
therefore that a proportion of patients are being transfused
unnecessarily. Given the risks associated with transfusion,
any measure decreasing the number of unnecessary trans-
fusions would be of benefit. Using tHb-mass as part of a
decision tool will provide a more accurate representation
of transfusion need and will allow the development of indi-
vidualized patient transfusion pathways, reducing risk ex-
posure. The most widely employed method to measure
tHb-mass is the optimized carbon monoxide (CO) re-
breathing method developed by Schmidt and Prommer
[87], though this is not currently in use in clinical medi-
cine. Briefly, a bolus of inhaled CO is used to ‘tag’ Hb, and
% HbCO in blood is measured before and (6 and 8 min)
after the bolus is delivered; using the Fick principle, the
tHb-mass can then be calculated. There are obvious diffi-
culties in adapting the CO re-breathing method of Schmidt
and Prommer to the intubated and ventilated patient.
Overcoming these issues would allow transfusion require-
ments to be more accurately judged and would yield add-
itional information such as an accurate calculation of the
circulating plasma volume - both would be extremely valu-
able in treating the critically ill patient.
Conclusions
Anaemia is ubiquitous in the critically ill population.
There seems to be two distinct phases: the acute phase
of the first 7 days during which the drop in [Hb] is
greatest and the chronic phase where [Hb] fails to re-
cover but does not decline at the same rate. The causesof anaemia in these phases differ (Figure 3), and most of
the quoted causes may contribute to the chronic an-
aemia but cannot explain the acute drop in [Hb]. Neocy-
tolysis is one mechanism by which such an acute fall in
[Hb] could occur, and if the theory of cellular hiberna-
tion is considered, then a programmed reduction in Hb
is logical. Neocytolysis has not yet been demonstrated in
the critically ill. Finally, the development of methods to
measure tHb-mass in this group is necessary if we are to
more accurately assess the transfusion needs of critically
ill patients.
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